Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. Ribas A, et al. Among authors: coffman rl. Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154193 Free PMC article. Clinical Trial.
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R. Frank MJ, et al. Among authors: coffman rl. Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154192 Free PMC article. Clinical Trial.
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. Garon EB, et al. Among authors: coffman rl. Clin Cancer Res. 2021 Aug 15;27(16):4566-4573. doi: 10.1158/1078-0432.CCR-21-0263. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108179 Clinical Trial.
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.
Jackson S, Candia AF, Delaney S, Floettmann S, Wong C, Campbell JD, Kell S, Lum J, Hessel EM, Traquina P, McHale M, Robinson I, Bell J, Fuhr R, Keeling D, Coffman RL. Jackson S, et al. Among authors: coffman rl. Clin Pharmacol Ther. 2018 Aug;104(2):335-345. doi: 10.1002/cpt.938. Epub 2017 Dec 6. Clin Pharmacol Ther. 2018. PMID: 29134633 Clinical Trial.
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE. Sato-Kaneko F, et al. Among authors: coffman rl. JCI Insight. 2017 Sep 21;2(18):e93397. doi: 10.1172/jci.insight.93397. eCollection 2017 Sep 21. JCI Insight. 2017. PMID: 28931759 Free PMC article.
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Friedberg JW, et al. Br J Haematol. 2009 Aug;146(3):282-91. doi: 10.1111/j.1365-2141.2009.07773.x. Epub 2009 Jun 10. Br J Haematol. 2009. PMID: 19519691 Free PMC article. Clinical Trial.
264 results